Establishment of ELISA on 384-well microplate for AFP, CEA, CA 19-9, CA 15-3, CA 125, and PSA-ACT: Higher sensitivity and lower reagent cost

被引:19
|
作者
Wu, TL
Sun, YC
Chang, PY
Tsao, KC
Sun, CF
Wu, JT
机构
[1] Univ Utah, ARUP, Hlth Sci Ctr, Salt Lake City, UT 84108 USA
[2] Univ Utah, Dept Pathol, Hlth Sci Ctr, Salt Lake City, UT 84108 USA
[3] Chang Gung Mem Hosp, Dept Pathol, Taipei 10591, Taiwan
关键词
tumor marker; ELISA; 384-well microplate; 96-well microplate;
D O I
10.1002/jcla.10104
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The 384-well microplate contains four times as many wells as the regular 96-well microplate. Establishing enzyme linked immunosorbent assay (ELISA) on 384-well microplate should lead to savings in reagents and specimens. To determine that ELISAs on 384-well microplate have acceptable assay precision, ELISAs for tumor markers, including AFP, PSA-ACT, CEA, CA 125, CA 15-3, and CA 19-9, were compared to the same ELISAs established on 96-well microplate. We found that ELISAs established on 384-well microplate had similar sensitivity and covered similar concentration ranges as ELISAs on 96-well microplate. All within-day and day-to-day precisions for the 384-ELISA had %CV less than 10%. Compared to ELISA on 96-well microplate, 384-ELISA used less reagents, less specimen, and exhibited approximately a two-fold increase in sensitivity. Overall cost of the 384-384-ELISA was also greatly reduced. Our results suggest that 384-ELISA is suitable for use in routine clinical laboratories. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:241 / 246
页数:6
相关论文
共 41 条
  • [1] Development of ELISA on 384-well microplate for AFP,CA125,CA19-9 and CA15-3: higher test sensitivity and lower reagent cost.
    Chang, PY
    Wu, JT
    Sun, YC
    CLINICAL CHEMISTRY, 2001, 47 (06) : A125 - A126
  • [2] Screening asymptomatic population for cancer by measuring serum PSA, CEA, AFP, CA 19-9, CA 125 and CA 15-3: Taiwan experience.
    Tsao, K
    Sun, C
    Wu, JT
    CLINICAL CHEMISTRY, 2000, 46 (06) : A162 - A162
  • [3] Serum CA 125, CA 15-3, CEA, and CA 19-9: a prognostic factor for uterine carcinosarcomas?
    Thomakos, Nikolaos
    Rodolakis, Alexandros
    Zagouri, Flora
    Zacharakis, Dimitrios
    Sotiropoulou, Maria
    Akrivos, Nikolaos
    Haidopoulos, Dimitrios
    Papadimitriou, Christos A.
    Dimopoulos, Meletios-Athanassios
    Antsaklis, Aris
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2013, 287 (01) : 97 - 102
  • [4] Serum CA 125, CA 15-3, CEA, and CA 19-9: a prognostic factor for uterine carcinosarcomas?
    Nikolaos Thomakos
    Alexandros Rodolakis
    Flora Zagouri
    Dimitrios Zacharakis
    Maria Sotiropoulou
    Nikolaos Akrivos
    Dimitrios Haidopoulos
    Christos A. Papadimitriou
    Meletios-Athanassios Dimopoulos
    Aris Antsaklis
    Archives of Gynecology and Obstetrics, 2013, 287 : 97 - 102
  • [5] Serum concentrations of CA 125, CA 15-3, CA 19-9 and CEA in normal pregnancy: a longitudinal study
    Ercan, Serif
    Kaymaz, Ozge
    Yucel, Nihal
    Orcun, Asuman
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2012, 285 (03) : 579 - 584
  • [6] Serum concentrations of CA 125, CA 15-3, CA 19-9 and CEA in normal pregnancy: a longitudinal study
    Şerif Ercan
    Özge Kaymaz
    Nihal Yücel
    Asuman Orçun
    Archives of Gynecology and Obstetrics, 2012, 285 : 579 - 584
  • [7] Menstrual cycle dependent variability for serum tumor markers CEA, AFP, CA 19-9, CA 125 and CA 15-3 in healthy women
    Erbagci, AB
    Yilmaz, N
    Kutlar, I
    DISEASE MARKERS, 1999, 15 (04) : 259 - 267
  • [8] Longitudinal evaluation of external quality assessment results for CA 15-3, CA 19-9, and CA 125
    Kremser, Marcel
    Weiss, Nathalie
    Kaufmann-Stoeck, Anne
    Vierbaum, Laura
    Schmitz, Arthur
    Schellenberg, Ingo
    Holdenrieder, Stefan
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2024, 11
  • [9] Development of tumor marker ELISA tests for the direct quantitation. of CA 19-9, CA 125, CEA, AFP, and total PSA in clinical routine.
    Janetzko, A
    Bauer, K
    Dudek, T
    Brahms, H
    Geacintov, CE
    CLINICAL CHEMISTRY, 2005, 51 : A58 - A58
  • [10] EFFICACY OF CARBOHYDRATE ANTIGENS (CA 19-9, CA 125, CA 15-3) FOR DIAGNOSIS AND PROGNOSTIC FACTORS OF BLADDER TUMOR
    Kosan, Murat
    Tul, Mesut
    Gonulalan, Umut
    Ugurlu, Ozgur
    Inal, Gurdal
    Adsan, Oztug
    TURKISH JOURNAL OF UROLOGY, 2008, 34 (02): : 155 - 160